Daewon Pharmaceutical shares up 16% on successful P-CAB phase 3 trial [Why Bio]
Predicted impact: Medium
Phase 3 success for P-CAB drug; stock already surged 16%, but approval filing still pending.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.